Author:
Sutani A,Nagai Y,Udagawa K,Uchida Y,Koyama N,Murayama Y,Tanaka T,Miyazawa H,Nagata M,Kanazawa M,Hagiwara K,Kobayashi K
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MJ, Baselga J, Ochs JS, Haber DA (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT Gefitinib Trials. J Clin Oncol 23: 8081–8092
2. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl S, Cotton M, Kéri G, Wissing J, Daub H (2005) Cellular targets of gefitinib. Cancer Res 65: 379–382
3. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037–1057
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237–2246
5. Hirsch FR, Franklin WA, McCoy J, Cappuzzo F, Varella-Garcia M, Witta SE, Gumerlock P, West H, Gandara DR, Bunn Jr PA (2006) Predicting clinical benefit from EGFR TKIs: not all EGFR mutations are equal. Proc Am Soc Clin Oncol 24 (18S): 382s
Cited by
149 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献